A Look at Alkermes (ALKS) Valuation Following Q3 Earnings Beat and Raised 2025 Outlook

Simply Wall St.12-01

Alkermes (ALKS) gained attention after its third quarter earnings surpassed consensus expectations. Sales growth from Vivitrol, Aristada, and Lybalvi contributed to this performance. The company also ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588488718?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-12-01 01:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588488718","market":"hk","top_or_hot":-1,"title":"A Look at Alkermes (ALKS) Valuation Following Q3 Earnings Beat and Raised 2025 Outlook","media":"Simply Wall St.","content":"<div>\n<p>Alkermes (ALKS) gained attention after its third quarter earnings surpassed consensus expectations. Sales growth from Vivitrol, Aristada, and Lybalvi contributed to this performance. The company also ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/a-look-at-alkermes-alks-valuation-following-q3-earnings-beat\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look at Alkermes (ALKS) Valuation Following Q3 Earnings Beat and Raised 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look at Alkermes (ALKS) Valuation Following Q3 Earnings Beat and Raised 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-01 01:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/a-look-at-alkermes-alks-valuation-following-q3-earnings-beat><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alkermes (ALKS) gained attention after its third quarter earnings surpassed consensus expectations. Sales growth from Vivitrol, Aristada, and Lybalvi contributed to this performance. The company also ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/a-look-at-alkermes-alks-valuation-following-q3-earnings-beat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALKS","symbol_name":"阿尔凯默斯","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/a-look-at-alkermes-alks-valuation-following-q3-earnings-beat","article_id":"2588488718","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/a-look-at-alkermes-alks-valuation-following-q3-earnings-beat","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2588488718","pubTimestamp":1764522684,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Alkermes (ALKS) gained attention after its third quarter earnings surpassed consensus expectations. Sales growth from Vivitrol, Aristada, and Lybalvi contributed to this performance. The company also raised its outlook for 2025 revenues.\nSee our latest analysis for Alkermes.\nAlkermes’ upbeat third quarter results and guidance boost have kept investor attention on its growth potential, even as the company prepares to acquire Avadel Pharmaceuticals early next year. The momentum from a 16%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ALKS":"阿尔凯默斯"},"translate_title":"第三季度盈利超出预期并上调2025年前景后审视Alkermes(ALKS)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALKS":1.5},"content_text":"Alkermes (ALKS) gained attention after its third quarter earnings surpassed consensus expectations. Sales growth from Vivitrol, Aristada, and Lybalvi contributed to this performance. The company also raised its outlook for 2025 revenues. See our latest analysis for Alkermes. Alkermes’ upbeat third quarter results and guidance boost have kept investor attention on its growth potential, even as the company prepares to acquire Avadel Pharmaceuticals early next year. The momentum from a 16% increase in proprietary product sales is reflected in a 2.9% year-to-date share price return, and its 57.6% total shareholder return over five years highlights steady long-term gains. Still, with only modest movement over the past month, the market seems to be weighing recent wins against broader biopharma competition and valuation questions. If Alkermes’ renewed momentum has you scanning for more opportunities, this could be the perfect moment to expand your horizons and discover fast growing stocks with high insider ownership The question now is whether Alkermes’ recent outperformance and raised targets signal an undervalued opportunity for investors, or if the current share price already reflects expectations for continued growth and upcoming acquisitions. AdvertisementMost Popular Narrative: 32.6% Undervalued Those following the most influential narrative for Alkermes will notice the fair value estimate is much higher than the current share price. This suggests some investors see room for significant upside from today's level. Attention is now on what drives this optimistic view and whether these projections can stand the test of time.  Robust, above-expectation demand growth for Alkermes' proprietary neuroscience products (Vivitrol, Aristada, and Lybalvi), supported by expanding diagnosis rates and increased patient access through Medicaid and insurance, drives outsized revenue expansion and positions the company for continued top-line growth as global awareness of mental health disorders rises.  Read the complete narrative. Want to know what powers that elevated price target? The driving factors include aggressive growth targets for both sales and profit margins, as well as a bold new multiple that few would expect. Curious which unconventional assumptions ground this fair value call? Explore the full narrative to reveal the surprising levers behind the valuation. Result: Fair Value of $43.88 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, rising R&D costs and significant dependence on a small number of proprietary products could quickly challenge the current positive outlook for Alkermes. Find out about the key risks to this Alkermes narrative.  Build Your Own Alkermes Narrative If you see the story differently or want to dive into the details on your own terms, you can quickly create your own perspective with all the data in front of you. Do it your way A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Alkermes. Looking for more investment ideas? Don’t just watch from the sidelines while smarter investors find their next portfolio win. The right stock could be waiting among today’s breakout opportunities.  Boost your passive income by uncovering top picks among these 15 dividend stocks with yields > 3% with yields exceeding 3%. This can provide your portfolio with an immediate income advantage. Spot tomorrow’s potential tech leaders by targeting these 25 AI penny stocks that use artificial intelligence to transform industries and strive for market-beating growth. Seize the moment with these 914 undervalued stocks based on cash flows that offer attractive value based on cash flows before the rest of the market takes notice.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588488718","isCrawlerRequest":true}